Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > CEO Busy

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Dec 20, 2022 12:09pm

136 Views

Post# 35182350

RE:CEO Busy

From Twitter:

"RepliCel Life Sciences Inc.

@RepliCel

21h

 			We just arrived in Japan! We are meeting with multiple potential investors and partners for all of our products: RCH-01 for regrowing hair, RCS-01 for rejuvenating skin, RCT-01 for repairing tendons,& DermaPrecise for precision injections. CEO Andrew Schutte is busy. Stay tuned."
 			
 			Good to see Replicel back on Twitter. I used to be a bit jaded when it came to Replicel tweeting useless information then they went to no tweets. I take it back, it is good to see them using Twitter to keep the shareholders informed as long as it is useful information.
 			It will be interesting to see how this trip turns out. According to the tweet all of their assets will be in play. Most importantly I hope they do find some new investors with "deep pockets". Possibly they are lining up a potential distributor for Dermaprecise.
 			There is so much riding on this Arbitration with Shiseido . If the judgement involves the Asian RCH-01 license being returned to Replicel I imagine they are talking to interested Japanese companies that might want to pick up this license. I think this trip to Japan is also an "in your face" show of strength to Shiseido and it might be in their best interest to settle this dispute.